Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS207 +/- JS007 in advanced HCC
NCT06954467Phase 2Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of JS207 in hepatocellular carcinoma (HCC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started May 2025; status: recruiting.
02
Drugs
JS207
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06954467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954467.